Dominika Kovacs – Country Manager, Takeda Romania
Dominika Kovacs, country manager of Takeda Romania, shares her insights on the growing pipeline of the organisation and the anticipated launch of a…
Tagged with M&A
Kieran Leahy – General Manager, Takeda Czech Republic…
Kieran Leahy, general manager of Takeda in the Czech Republic and Slovakia, recounts how he has led the transformation of Takeda into a specialty care…
Life Sciences’ Growing Demand for AI Assets
Digital health deal values in biopharma jumped to USD 6.4 billion in 2019, largely thanks to software company Dassault Systemes Americas Corp.’s…
A Pharma Funding Overview & Outlook for 2020
Michael Jewell, partner and head of healthcare & life sciences at Cavendish Corporate Finance looks back at the key trends across pharma industry…
Zentiva’s Aggressive Internationalization Strategy
Despite being recently divested from multinational pharma giant Sanofi, Czech firm Zentiva is becoming one of the fastest-growing generics…
Private Equity Targeting Healthcare & Consulting Comms…
Anthony Harrington of global investment banking and asset management firm Alantra outlines why healthcare and consulting communications companies are…
Kristina Willgård – CEO, AddLife, Sweden
AddLife is a Swedish company that acquires and streamlines profitable market-leading niche companies in the field of life science. CEO Kristina…
Joacim Lindoff – CEO, Arjo
Changing demographics and revolutionary technological advancements are altering the structure of the medtech industry paving the way for Arjo, a…
Christoffer Lorenzen – CEO, Karo Pharma, Sweden
Karo Pharma is a Swedish specialty pharma company that develops and markets products to pharmacies and healthcare providers. CEO Christoffer Lorenzen…
AI in Healthcare M&A: On the Rise
David H. Crean, managing director for Objective Capital Partners, highlights the latest trends in mergers and acquisition (M&A) activities…
Aspen Spain: Thriving on Change
The global acquisition of GSK’s thrombosis portfolio and subsequent purchase of AstraZeneca’s anaesthesia business have been critical milestones…
Bayer: Betting Big on Cell & Gene Therapy
Bayer’s latest move to buy out BlueRock Therapeutics comes with a price tag of USD 600 million in total as the company increasingly looks toward…
